Inaccurate Self-Monitoring of Blood Glucose Readings in Patients on Chronic Ambulatory Peritoneal Dialysis with Icodextrin

Abstract

Patients on chronic ambulant peritoneal dialysis (CAPD) are increasingly likely to be treated with a new solution of corn starch-derived glucose polymers called icodextrin. This solution involves a very low carbohydrate absorption leading to a better glycemic control in diabetic patients. However these glucose polymers pass to the blood and are metabolized to oligosaccharids which interfere with blood glucose in distinct capillary glucose analyzers leading to overestimation of glycemia. We assessed the accuracy of glucose measurements with the three most commonly used glucose analyzers compared to venous plasma glucose measurement at our institution in 8 patients (4 patients with type 2 diabetes) on CAPD using icodextrin. Glycemia was measured simultaneously in plasma of venous blood using a reference laboratory method and in capillary blood using Accu-Chek sensor® (Rotkreuz, Switzerland) (glucose dehydrogenase method), Glucotrend 2® (Rotkreuz, Switzerland) (glucose-dye-oxyreductase method) and Ascensia elite® (Zurich, Switzerland) (glucose oxidase method) glucose analyzers. Only glucose readings with Ascensia elite® correspond correctly with venous plasma glucose results (+ 0.3 mmol/l; n. s.), whereas glycemia was significantly overestimated by Accu-Chek sensor® (+ 4.3 mmol/l; p < 0. 0001) and Glucotrend 2® glucose analyzers (+ 3.7 mmol/l; p < 0. 0001). Thus we conclude that distinct glucose analyzers overestimate real blood glucose concentration and are not suitable for monitoring glycemia in patients on CAPD with icodextrin. On the basis of our results, these patients should use glucose analyzers using glucose oxidase methods. All glucose analyzers should be cross-checked with a laboratory reference method before the application in patients on CAPD with icodextrin is recommended.

Peritoneal dialysis - icodextrin - blood glucose

References

• 1 Disse E, Thivolet C. Related hypoglycemic coma in a diabetic patient on peritoneal dialysis due to interference of icodextrin metabolites with capillary blood glucose measurements.  Diabetes Care. 2004;  27 2279
• 2 Frampton J E, Plosker G L. Icodextrin: a review of its use in peritoneal dialysis.  Drugs. 2003;  63 2079-2105
• 3 Gokal R, Moberly J, Lindholm B, Mujais S. Metabolic and laboratory effects of icodextrin.  Kidney Int. 2002;  81 S62-S71
• 4 Johnson D W, Agar J, Collins J, Disney A, Harris D C, Ibels L, Irish A, Saltissi D, Suranyi M. Recommendations for the use of icodextrin in peritoneal dialysis patients.  Nephrology. 2003;  8 1-7
• 5 Krediet R T, van Westrhenen R, Zweers M M, Struijk D G. Clinical advantages of new peritoneal dialysis solutions.  Nephrol Dial Transplant. 2002;  17 S16-S18
• 6 Mehmet S, Quan G, Thomas S, Goldsmith D. Important causes of hypoglycaemia in patients with diabetes on peritoneal dialysis.  Diabet Med. 2001;  18 679-682
• 7 Oyibo S O, Pritchard G M, McLay L, James E, Laing I, Gokal R, Boulton A J. Blood glucose overestimation in diabetic patients on continuous ambulatory peritoneal dialysis for end-stage renal disease.  Diabet Med. 2002;  19 693-696
• 8 Riley S G, Chess J, Donovan K L, Williams J D. Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid.  BMJ. 2003;  327 608-609
• 9 Wens R, Taminne M, Devriendt J, Collart F, Broeders N, Mestrez F, Germanos H, Dratwa M. A previously undescribed side effect of icodextrin: overestimation of glycemia by glucose analyzer.  Perit Dial Int. 1998;  18 603-609